Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CHD
MCID: CRN300
MIFTS: 61

Coronary Heart Disease 1 (CHD)

Categories: Blood diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Coronary Heart Disease 1

About this section

MalaCards integrated aliases for Coronary Heart Disease 1:

Name: Coronary Heart Disease 1 58 30
Coronary Heart Disease 58 77 30 56 6 64 17 74
Coronary Heart Disease, Susceptibility to, 1 58 74
Coronary Heart Disease, Susceptibility to 58 13
Heart, Coronary, Disease, Susceptibility to, Type 1 41
Coronary Arteriosclerosis 74
Coronary Artery Disease 74
Chds1 58
Chd 49

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Coronary Heart Disease 1

About this section
PubMed Health : 64 About coronary heart disease: Coronary heart disease (CHD) is a disease in which a waxy substance called plaque (plak) builds up inside the coronary arteries. These arteries supply oxygen-rich blood to your heart muscle.When plaque builds up in the arteries, the condition is called atherosclerosis (ATH-er-o-skler-O-sis). The buildup of plaque occurs over many years.

MalaCards based summary : Coronary Heart Disease 1, also known as coronary heart disease, is related to diabetes mellitus, noninsulin-dependent and lung cancer, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Coronary Heart Disease 1 is APOC3 (Apolipoprotein C3), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Atorvastatin and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes.

Wikipedia : 77 Coronary artery disease (CAD), also known as ischemic heart disease (IHD), involves the reduction of... more...

Description from OMIM: 607339
Sources

Related Diseases for Coronary Heart Disease 1

About this section

Diseases in the Coronary Heart Disease 1 family:

Coronary Heart Disease 3 Coronary Heart Disease 2
Coronary Heart Disease 4 Coronary Heart Disease 5
Coronary Heart Disease 7 Coronary Heart Disease 8
Coronary Heart Disease 9 Coronary Heart Disease 6

Diseases related to Coronary Heart Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 339)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, noninsulin-dependent 31.7 APOC3 CDKN2B-AS1 GAS5 MIR126 SOCS1 WFDC21P
2 lung cancer 30.6 CDKN2A CDKN2B CDKN2B-AS1 GAS5 H19 HOTTIP
3 gastric cancer 30.6 CDKN2A CDKN2B CDKN2B-AS1 GAS5 H19 HOTTIP
4 colorectal cancer 30.5 CDKN2A CDKN2B-AS1 GAS5 H19 HOTTIP MIR126
5 esophageal cancer 30.5 CDKN2A CDKN2B CDKN2B-AS1 GAS5 H19 HOTTIP
6 endometriosis 30.4 CDKN2B-AS1 H19 MIR126 MIR145
7 ovarian cancer 30.2 CDKN2B CDKN2B-AS1 GAS5 H19 MIR126 MIR145
8 prostate cancer 30.2 CDKN2B-AS1 GAS5 H19 HOTTIP IGF2-AS MIR126
9 coronary artery anomaly 12.1
10 coronary heart disease 2 11.6
11 coronary heart disease 4 11.6
12 coronary heart disease 5 11.6
13 heart disease 11.6
14 hyperlipidemia, familial combined 11.5
15 coronary heart disease 3 11.5
16 coronary heart disease 7 11.5
17 coronary heart disease 8 11.5
18 coronary heart disease 9 11.5
19 coronary heart disease 6 11.5
20 hypercholesterolemia, familial 11.5
21 angina pectoris 11.5
22 hypoalphalipoproteinemia, primary 11.4
23 abdominal obesity-metabolic syndrome 1 11.4
24 cardiac arrest 11.4
25 cleft palate, cardiac defect, genital anomalies, and ectrodactyly 11.3
26 hyperlipoproteinemia, type iii 11.2
27 high density lipoprotein cholesterol level quantitative trait locus 1 11.2
28 total anomalous pulmonary venous return 1 11.2
29 hyperlipidemia, combined, 1 11.1
30 8p23.1 duplication syndrome 11.0
31 diabetes mellitus 10.8
32 depression 10.7
33 myocardial infarction 10.7
34 rere-related disorders 10.6
35 chlamydia pneumonia 10.6
36 chlamydia 10.6
37 pancreatic ductal adenocarcinoma 10.5 H19 HOTTIP MIR145 MIR155
38 melanoma-pancreatic cancer syndrome 10.5 CDKN2A CDKN2B-AS1
39 thyroid cancer, nonmedullary, 1 10.5 GAS5 H19 HOTTIP MIR155
40 kidney cancer 10.5 GAS5 H19 MIR126 MIR17 MIR182
41 malignant glioma 10.5 CDKN2B-AS1 GAS5 HOTTIP
42 prostate disease 10.5 CDKN2B-AS1 GAS5 H19 IGF2-AS
43 osteogenic sarcoma 10.5 CDKN2B-AS1 GAS5 H19 HOTTIP
44 laryngeal squamous cell carcinoma 10.5 CDKN2A CDKN2B-AS1 H19
45 nervous system cancer 10.5 CDKN2A CDKN2B CDKN2B-AS1
46 anxiety 10.5
47 adamantinoma of long bones 10.5 CDKN2A CDKN2B-AS1 GAS5 H19 HOTTIP
48 tenosynovial giant cell tumor 10.5 CDKN2A CDKN2B
49 acute lymphocytic leukemia 10.5 CDKN2A CDKN2B CDKN2B-AS1
50 leukemia, acute myeloid 10.5 CDKN2B CDKN2B-AS1 MIR126 MIR155 MIR182

Graphical network of the top 20 diseases related to Coronary Heart Disease 1:



Diseases related to Coronary Heart Disease 1
Sources

Symptoms & Phenotypes for Coronary Heart Disease 1

About this section

Clinical features from OMIM:

607339

UMLS symptoms related to Coronary Heart Disease 1:


tremor, angina pectoris, edema, chest pain, equilibration disorder, substernal pain
Sources

Drugs & Therapeutics for Coronary Heart Disease 1

About this section

PubMedHealth treatment related to Coronary Heart Disease 1: 64

Treatments for coronary heart disease (CHD) include lifestyle changes, medicines, and medical procedures. Treatment goals may include:Relieving symptoms.Reducing risk factors in an effort to slow, stop, or reverse the buildup of plaque.Lowering the risk of blood clots forming. (Blood clots can cause a heart attack.)Widening or bypassing clogged arteries.Preventing complications of CHD.

Drugs for Coronary Heart Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 134523-00-5 60823
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 11128-99-7, 68521-88-0, 4474-91-3 172198
3
Olmesartan Approved, Investigational Phase 4,Phase 2 144689-24-7, 144689-63-4 158781 130881
4
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 70789204 6442177
5
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 5284616 6436030
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
7
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
8
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
9
Trimetazidine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5011-34-7
10
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
11
Isosorbide Dinitrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 87-33-2 6883
12
AT-101 Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 90141-22-3, 652-67-5 12597
13
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 37350-58-6, 51384-51-1 4171
14
Ticagrelor Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 274693-27-5 9871419
15
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 73963-72-1 2754
16 Nutmeg Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17
Tirofiban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144494-65-5 60947
18
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
19
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
20
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
21
Insulin glargine Approved Phase 4,Phase 3 160337-95-1
22
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
23
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051
24
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
25
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 88150-42-9 2162
26
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
27
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
28
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 95635-55-5, 142387-99-3 56959
29
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 54678486 6691
30
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
31
Cobalt Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-48-4 104729
32
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-47-3 27668
33
Alprostadil Approved, Investigational Phase 4,Phase 3 745-65-3 5280723 149351
34
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
35
Pitavastatin Approved Phase 4,Phase 3,Not Applicable 147511-69-1, 147526-32-7 5282452 6366718
36
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 122320-73-4 77999
37
Lovastatin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 75330-75-5 53232
38
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 163222-33-1 150311
39
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 72956-09-3 2585
40
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1406-66-2 14986
41
Regadenoson Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 313348-27-5 219024
42
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-32-2 3108
43
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
44
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
45
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
46
Sufentanil Approved, Investigational Phase 4,Not Applicable 56030-54-7 41693
47
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1401-55-4
48
Etomidate Approved Phase 4 33125-97-2 667484 36339
49
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 113775-47-6 5311068 68602
50
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28523-86-6 5206

Interventional clinical trials:

(show top 50) (show all 8312)
# Name Status NCT ID Phase Drugs
1 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
2 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
3 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
4 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
5 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
6 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
7 Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
8 Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
9 Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease Unknown status NCT02514642 Phase 4 low-dose ticagrelor;Clopidogrel
10 The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
11 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
12 Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
13 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques Unknown status NCT01773512 Phase 4 Rosuvastatin
14 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
15 Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
16 Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
17 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
18 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
19 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
20 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
21 The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
22 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
23 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM) Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
24 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
25 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
26 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
27 Comparison of Biomatrix and Orsiro Drug Eluting Stent Unknown status NCT02299011 Phase 4 Biomatrix drug eluting stent
28 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
29 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
30 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
31 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
32 Fluvastatin AmelIorates aTHerosclerosis Study Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
33 Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
34 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
35 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
36 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
37 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
38 PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes Unknown status NCT03159559 Phase 4 Lipo-PGE1
39 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
40 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
41 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
42 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
43 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
44 PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
45 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
46 Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI Unknown status NCT01781715 Phase 4
47 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM) Unknown status NCT02044250 Phase 4 Clopidogrel;Aspirin
48 Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients Unknown status NCT01807078 Phase 4 Ezetimibe
49 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
50 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4

Search NIH Clinical Center for Coronary Heart Disease 1

Inferred drug relations via UMLS 74 / NDF-RT 52 :
Sources

Genetic Tests for Coronary Heart Disease 1

About this section

Genetic tests related to Coronary Heart Disease 1:

# Genetic test Affiliating Genes
1 Coronary Heart Disease 1 30 CX3CR1
2 Coronary Heart Disease 30
Sources

Anatomical Context for Coronary Heart Disease 1

About this section

MalaCards organs/tissues related to Coronary Heart Disease 1:

42
Heart, Endothelial, Testes, Bone, Kidney, Bone Marrow, Breast
Sources

Publications for Coronary Heart Disease 1

About this section

Articles related to Coronary Heart Disease 1:

(show top 50) (show all 4751)
# Title Authors Year
1
Psychological traits, heart rate variability, and risk of coronary heart disease in healthy aging women - the Women's Health Initiative. ( 30688770 )
2019
2
Multi-state models of transitions in depression and anxiety symptom severity and cardiovascular events in patients with coronary heart disease. ( 30845176 )
2019
3
Clinical study of chlamydia pneumoniae infection in patients with coronary heart disease. ( 31088358 )
2019
4
Intake of 12 food groups and disability-adjusted life years from coronary heart disease, stroke, type 2 diabetes, and colorectal cancer in 16 European countries. ( 31030306 )
2019
5
Associations of calcium and dairy product intakes with all-cause, all-cancer, colorectal cancer, and coronary heart disease mortality among older women in the Iowa Women's Health Study. ( 30834851 )
2019
6
New Insights Into the Comorbidity of Coronary Heart Disease and Depression. ( 31005351 )
2019
7
Clarifying the Concept of Depression in Women With Coronary Heart Disease. ( 30864985 )
2019
8
Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. ( 30886334 )
2019
9
Effect of text messaging on depression in patients with coronary heart disease: a substudy analysis from the TEXT ME randomised controlled trial. ( 30787075 )
2019
10
Depression and coronary heart disease: 2018 ESC position paper of the working group of coronary pathophysiology and microcirculation developed under the auspices of the ESC Committee for Practice Guidelines. ( 30698764 )
2019
11
Higher rates of depression among women living with Coronary Heart Disease are associated with poorer treatment outcomes and prognosis. ( 30661009 )
2019
12
Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. ( 30651799 )
2019
13
Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. ( 30423457 )
2019
14
A patient with T4 esophageal cancer cured by radical resection combined with an aortic arch aneurysm, coronary heart disease, hypertension, diabetes, and other high-risk factors. ( 30947500 )
2019
15
FEATURES OF ENDOTHELIAL DYSFUNCTION IN ELDERLY PERSONS WITH CORONARY HEART DISEASE AND CONCOMITANT GASTROESOPHAGEAL REFLUX DISEASE. ( 30958293 )
2019
16
Promotion of PTEN on apoptosis through PI3K/Akt signal in vascular smooth muscle cells of mice model of coronary heart disease. ( 31090947 )
2019
17
Vocational reintegration in coronary heart disease patients - the holistic approach of the WHO biopsychosocial concept. ( 31091981 )
2019
18
Metabolomic Pattern Predicts Incident Coronary Heart Disease. ( 31092011 )
2019
19
Letter by Khan et al Regarding Article, "Artificially Sweetened Beverages and Stroke, Coronary Heart Disease, and All-Cause Mortality in the Women's Health Initiative". ( 31092156 )
2019
20
Letter by Pyrogianni and La Vecchia Regarding Article, "Artificially Sweetened Beverages and Stroke, Coronary Heart Disease, and All-Cause Mortality in the Women's Health Initiative". ( 31092161 )
2019
21
Response by Mossavar-Rahmani and Wassertheil-Smoller to Letters Regarding Article, "Artificially Sweetened Beverages and Stroke, Coronary Heart Disease, and All-Cause Mortality in the Women's Health Initiative". ( 31092164 )
2019
22
Coronary Heart Disease and ABO Blood Group in Diabetic Women: A Case-Control Study. ( 31092877 )
2019
23
Endothelial dysfunction in patients with chronic obstructive pulmonary disease in combination with coronary heart disease. ( 31094454 )
2019
24
The marker of adverse prognosis 1.5-anhydroglucitol in patients with coronary heart disease in the long-term period after planned myocardial revascularization. ( 31094476 )
2019
25
Circulating phylloquinone, inactive Matrix Gla protein and coronary heart disease risk: A two-sample Mendelian Randomization study. ( 31103344 )
2019
26
Gender disparities in patient education provided during patient visits with a diagnosis of coronary heart disease. ( 31106698 )
2019
27
Exploring the interplay between job strain and different domains of physical activity on the incidence of coronary heart disease in adult men. ( 31109187 )
2019
28
Metabolic and genetic profiling of young adults with and without a family history of premature coronary heart disease (MAGNETIC). Study design and methodology. ( 31110523 )
2019
29
Genetic polymorphisms of the SHBG gene can be the effect on SHBG and HDL-cholesterol levels in Coronary Heart Disease: a case-control study. ( 31111369 )
2019
30
Elevated plasma cystathionine is associated with increased risk of mortality among patients with suspected or established coronary heart disease. ( 31005968 )
2019
31
ABCA1 variants rs2230806 (R219K), rs4149313 (M8831I), and rs9282541 (R230C) are associated with susceptibility to coronary heart disease. ( 31006134 )
2019
32
Capsule Commentary on Yeh, et al., Depressed Mood, Perceived Health Competence and Health Behaviors: a Cross-Sectional Mediation Study in Outpatients with Coronary Heart Disease. ( 31011963 )
2019
33
Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. ( 31017618 )
2019
34
Anti-inflammatory and antioxidative effects of Dan-Lou tablets in the treatment of coronary heart disease revealed by metabolomics integrated with molecular mechanism studies. ( 31034953 )
2019
35
Association Between Neck Circumference and Coronary Heart Disease: A Meta-analysis. ( 31037271 )
2019
36
Iron in Coronary Heart Disease-J-Shaped Associations and Ambivalent Relationships. ( 31040098 )
2019
37
Associations between nine candidate genetic polymorphisms with coronary heart disease : A meta-analysis. ( 31041492 )
2019
38
Exploring the relationship between coronary heart disease and type 2 diabetes: a cross-sectional study of secondary prevention among diabetes patients. ( 31049416 )
2019
39
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. ( 31054483 )
2019
40
Subgroups of monocytes predict cardiovascular events in patients with coronary heart disease.The PHAMOS trial (Prospective Halle Monocytes Study). ( 31055050 )
2019
41
Retinal and choroidal vascular changes in coronary heart disease: an optical coherence tomography angiography study. ( 31061756 )
2019
42
Comments on: "Association between miR-499 rs3746444 polymorphism and coronary heart disease susceptibility: An evidence-based meta-analysis of 5063 cases and 4603 controls". ( 31063798 )
2019
43
Effect of lifestyle focused text messaging on risk factor modification in patients with diabetes and coronary heart disease: A sub-analysis of the TEXT ME study. ( 31063856 )
2019
44
Asymmetric Dimethylarginine Predicts One-year Recurrent Cardiovascular Events: Potential Biomarker of "Toxin Syndrome" in Coronary Heart Disease. ( 31065970 )
2019
45
Targeted Sequencing Study to Uncover Shared Genetic Susceptibility Between Peripheral Artery Disease and Coronary Heart Disease. ( 31070467 )
2019
46
Comments on: "Association between the ICAM-1 gene polymorphism and coronary heart disease risk: a meta-analysis". ( 31072912 )
2019
47
Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease. ( 31075152 )
2019
48
Increase in pulse pressure on administration of a dental local anesthetic solution, prilocaine hydrochloride with felypressin in male diabetic patients with coronary heart disease. ( 31079247 )
2019
49
Effect of β-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis. ( 31080472 )
2019
50
Correlation of Circulating miR-765, miR-93-5p, and miR-433-3p to Obstructive Coronary Heart Disease Evaluated by Cardiac Computed Tomography. ( 31084998 )
2019